Rib-X Pharmaceuticals

[http://www.rib-x.com Rib-X Pharmaceuticals] is a privately-held New Haven, Connecticut based development-stage biopharmaceutical company, founded in 2001 to develop small-molecule antibiotics to treat serious multi-drug resistant bacterial infections. Rib-X's compounds (two of which are in Phase 2 clinical trials) include those that may treat many of the [http://www.idsociety.org/Content.aspx?id=3530 pathogens on the 2006 IDSA hit list of dangerous microbes] , including Methicillin-resistant Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

The company's drug development technology is inspired by its Scientific and Clinical Advisory boards, which include: [http://www.yale.edu/steitz/ Thomas Steitz] , [http://proton.chem.yale.edu/ Peter Moore] , [http://rna.ucsc.edu/rnacenter/noller_lab.html Harry Noller] , Venki Ramakrishnan and [http://en.wikipedia.org/wiki/John_Abelson John Abelson] (focusing on the ribosome as an antibiotic target), William Jorgensen (focusing on computational drug discovery methods) and [http://www.rib-x.com/about_us/clinical_advisory_board Robert Moellering] , [http://www.tuftsmedicalcenter.org/OurServices/InfectiousDiseases/IDFacultyHelenWBoucher Helen Boucher] , [http://medicine.ucsf.edu/id/faculty/chambers.html Henry Chambers] , [http://gsbs.uth.tmc.edu/tutorial/murray.html Barbara Murray] , [http://www.rib-x.com/about_us/smith Leon Smith] and [http://www.people.vcu.edu/~rwenzel/ Richard Wenzel] (focusing on infectious disease and the problems of antibiotic-resistance).

Sources:

1. [http://www.nhregister.com/articles/2006/06/02/import/16726737.txt Company Gets Rights for New Antibiotic (New Haven Register)]